A standard of care, grounded in research

There is a large and compelling body of clinical evidence showing that, for many cancers, proton therapy is overall safer and more effective than conventional radiation, particularly for complex and difficult-to-treat tumors.

 

And yet, many insurance companies still deny coverage. Which is a key reason the New York Proton Center invests so heavily in proton therapy research.

 

The New York Proton Center has invested in a one-of-a-kind research program that aims to further the evidence supporting proton therapy and, in doing so, to make this potentially lifesaving treatment more widely available to patients.

 

A hub of advanced clinical research

The New York Proton Center has a large and productive research division. It’s a vibrant hub of activity—laboratory work, clinical trials, translational science, physics research—aimed at producing high quality data, driving best-practice guidelines, and reaffirming proton therapy as a well-accepted, standard-of-care treatment.

Clinical Trials

As one of its primary objectives, our dynamic research program is working to identify which patients stand to benefit most from proton therapy. To that end, all patients at the New York Proton Center are given an opportunity to enroll in clinical trials.

 

The first of these trials are comparing proton therapy to conventional treatment in the areas of breast cancer, head and neck cancers, and prostate cancer. Trials in numerous additional disease sites, as well as cancers that have recurrences following conventional radiation, will also soon be opened at the New York Proton Center.

 

Patients interested in participating in any of these trials should speak to their radiation oncologist about eligibility.

The following trials are currently enrolling patients:

Breast Cancer
  • Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer: PCG BRE 007: NCT01766297
Head and Neck Cancers
  • Evaluation of Automatic Anatomy Recognition for Radiation Therapy (AAR-RT) Methods and Software for Automated Organ-at-risk (OAR) Contouring in the Head and Neck (H&N) and Thorax for RT Planning/Replanning
Pediatric Cancers
  • Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated with Radiation Therapy. NCT01696721
Prostate Cancer
  • COMPPARE: Prospective comparative study of standard IMRT versus standard fractionation proton therapy for prostate cancer: NCT03561220
Thoracic Cancers
  • Evaluation of Automatic Anatomy Recognition for Radiation Therapy (AAR-RT) Methods and Software for Automated Organ-at-risk (OAR) Contouring in the Head and Neck (H&N) and Thorax for RT Planning/Replanning
All Cancer Types
  • Proton Collaborative Group REG001-09: Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy. NCT01255748
Approved by the FDA since 1988, proton therapy is firmly established as an advanced and highly effective treatment for cancer that can reduce treatment related toxicities, better preserve quality of life, and improve outcomes for patients.

How can we help?

Want to find out if proton therapy might be a good fit for you or your patient? Call us at 833-NYPROTON (833-697-7686) or fill out the appropriate form below.